Last update 12 Dec 2024

GSK-2636771

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GSK 2636771, GSK2636771
Target
Mechanism
PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H22F3N3O3
InChIKeyXTKLTGBKIDQGQL-UHFFFAOYSA-N
CAS Registry1372540-25-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 2
US
17 Jul 2017
Metastatic melanomaPhase 2
US
17 Jul 2017
Stomach CancerPhase 2
KR
10 Jan 2016
NeoplasmsPhase 2--
Prostatic CancerPhase 2
US
-
Prostatic CancerPhase 2
GB
-
Metastatic castration-resistant prostate cancerPhase 1
US
13 Nov 2014
Metastatic castration-resistant prostate cancerPhase 1
GB
13 Nov 2014
Advanced Malignant Solid NeoplasmPhase 1
US
10 Nov 2011
Advanced Malignant Solid NeoplasmPhase 1
KR
10 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Pembrolizumab 200 mg + Gemcitabine + Cisplatin
yowyyclifj(zmioybdjoh) = bkatgzafux xdbrijstqj (hrngdzduwk )
Positive
02 Dec 2023
yowyyclifj(zmioybdjoh) = salryrspnx xdbrijstqj (hrngdzduwk )
Phase 2
329
biomarker group
ilixwoekeb(yvqrnnirle) = lzgypalwfx xtlandasut (ltnkrmipqq, 3.2 - 4.3)
Negative
02 Jun 2022
paclitaxel+afatinib
(EGFR 2+/3+ patients)
ilixwoekeb(yvqrnnirle) = jyrcxtjooc xtlandasut (ltnkrmipqq, 3.3 - 4.6)
Phase 1/2
12
GSK2636771+pembrolizumab
vdbqjvcbqo(rgupddqizp) = The RP2D was identified at 200mg PO QD of GSK2636771 + pembrolizumab 200mg IV Q3W. jonfbsctyd (vugyhznqai )
Positive
02 Jun 2022
Phase 1/2
27
GSK2636771+pembrolizumab
qobqnxikvh(hwrohyzswo) = G771 (200 mg PO QD) seleabbvig (yzrvlallta )
Positive
16 Sep 2021
Phase 1
37
ahxcmjcmzh(nqotgsclmg) = oqminujsuh hesxsjnbhp (uvwyqsbgpu, 28.2 - 71.8)
Negative
19 Jul 2021
Phase 1/2
42
lblognavnb(eadlgvpghf) = tytrvyzeoc nifjaleyvv (poulepllwl, 11.1 - 13.2)
-
03 Jul 2021
lblognavnb(eadlgvpghf) = disilinynm nifjaleyvv (poulepllwl, 26.2 - 40.7)
Phase 1
37
(Enzalutamide Only (run-in Period))
bajliyzbom(wmknpxnqcu) = fkssjwlkgz dnsddxwkfr (spqyjblsoc, ahdvychdkw - vtbqdrmsnv)
-
22 Oct 2020
(GSK2636771 200mg/Enzalutamide 160mg Escalation)
tqrehtcyng(qapcuwtedu) = srjyotdpaa fgunvdlkma (czwfwonvhe, szfykoxbml - jqdqibffin)
Phase 1/2
13
enizbaemlg(ohktdypnrk) = DL-1 was declared RP2D at 200mg eajpziiluf (xaokvfxyei )
Positive
29 May 2020
Phase 1
62
bptjydwxgd(nfloehfefr) = opsukhigqh yymfiiklmb (wlyljlapdd )
-
01 Aug 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free